Ebixa

How to order Ebixa

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Ebixa on Prescriptsy

Ebixa is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Ebixa is the brand name for memantine hydrochloride, a prescription-only medicine used to treat moderate to severe Alzheimer's disease in adults.

Alzheimer's disease is the most common form of dementia in the United Kingdom, accounting for approximately 60 to 70% of all dementia cases.

It is a progressive neurodegenerative condition characterised by declining memory, cognitive function, language, and the ability to perform everyday tasks.

Ebixa works by modulating the activity of glutamate, a key neurotransmitter involved in learning and memory, to reduce the neuronal damage that drives disease progression.

While Ebixa does not cure Alzheimer's disease or stop it from getting worse, it can help to maintain function and slow the rate of decline, particularly in the moderate to severe stages.

Dementia affects approximately 900,000 people in the UK, a number projected to rise to over 1.5 million by 2040 as the population ages.

The impact extends far beyond the individual, placing significant demands on carers, families, and health and social care services.

For patients with moderate to severe Alzheimer's disease, treatment with memantine (alone or in combination with acetylcholinesterase inhibitors) represents one of the few pharmacological options shown to provide meaningful, if modest, clinical benefit.

This page provides a comprehensive clinical overview of Ebixa, covering how it works, who it is suitable for, dosage, expected benefits, side effects, important safety information, and how to access treatment in the UK.

Important safety information about Ebixa

Before reading further, note the following essential safety points. Ebixa is a prescription-only medicine (POM) that should be initiated by a specialist or a clinician experienced in dementia management.

• Ebixa is for moderate to severe Alzheimer's disease only. It is not indicated for mild Alzheimer's disease or other conditions.
• A carer should supervise administration, monitor for side effects, and attend review appointments with the patient.
• The dose must be increased gradually over 4 weeks (titration) to reduce the risk of side effects.
• Common side effects include headache, dizziness, constipation, and drowsiness; these usually settle with continued use.
• Seek urgent medical advice if the patient develops seizures, severe confusion, hallucinations, or breathing difficulties.

Understanding Alzheimer's disease and the role of glutamate

Alzheimer's disease involves the progressive accumulation of abnormal protein deposits in the brain: amyloid-beta plaques between neurons and tau neurofibrillary tangles within neurons.

These pathological changes trigger a cascade of events including chronic neuroinflammation, synaptic dysfunction, and neuronal death, leading to the clinical symptoms of memory loss, confusion, disorientation, and eventual loss of independence.

Glutamate is the brain's primary excitatory neurotransmitter, essential for learning, memory formation, and synaptic plasticity.

Under normal conditions, glutamate activates NMDA receptors briefly during synaptic signalling, allowing calcium influx that is part of normal neuronal communication.

In Alzheimer's disease, however, damaged neurons release excessive amounts of glutamate, causing sustained, low-level activation of NMDA receptors.

This chronic overactivation produces a constant influx of calcium ions into neurons, leading to excitotoxic damage, impaired synaptic signalling, and accelerated cell death.

This glutamate-driven excitotoxicity creates a form of background noise that interferes with normal synaptic transmission, making it harder for the brain to form and retrieve memories. It also contributes directly to the progressive neuronal loss that characterises the disease.

How Ebixa works: mechanism of action

Memantine is a moderate-affinity, uncompetitive NMDA receptor antagonist.

Unlike competitive antagonists that would block all NMDA receptor activity (including the physiological signalling essential for cognition), memantine selectively targets the pathological tonic activation caused by excess glutamate while preserving the phasic signalling needed for memory and learning.

The key to memantine's selectivity is its voltage-dependent binding kinetics.

Under normal resting conditions (when the neuron is not actively signalling), memantine sits in the NMDA receptor ion channel and blocks the entry of calcium ions, protecting the neuron from the damaging effects of low-level tonic glutamate stimulation.

When a strong physiological signal arrives (a genuine synaptic event associated with learning or memory), the resulting depolarisation of the neuronal membrane displaces memantine from the channel, allowing the normal calcium influx to occur.

Once the signal has passed, memantine re-enters the channel and resumes its protective blockade.

This dual action reduces pathological noise while preserving signal, improving the signal-to-noise ratio in glutamate neurotransmission.

The clinical consequence is a slowing of cognitive and functional decline, with some patients experiencing stabilisation or even modest improvement in symptoms during the early months of treatment.

Clinical evidence and NICE guidance

Memantine's efficacy has been demonstrated in multiple randomised, double-blind, placebo-controlled clinical trials involving patients with moderate to severe Alzheimer's disease (Mini-Mental State Examination scores typically below 20).

These trials consistently showed that memantine produced statistically significant improvements compared with placebo on measures of cognition (using scales such as the Severe Impairment Battery, SIB), global clinical impression (CIBIC-Plus), functional ability (ADCS-ADL), and behavioural symptoms (Neuropsychiatric Inventory, NPI).

NICE technology appraisal TA217 (last updated 2011, with subsequent review confirming recommendations) recommends memantine as a treatment option for people with moderate Alzheimer's disease who are intolerant of or have a contraindication to acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine), and for people with severe Alzheimer's disease.

Memantine may also be used in combination with an acetylcholinesterase inhibitor for moderate to severe disease.

Treatment should be initiated and monitored by a clinician experienced in dementia care.

The Alzheimer's Society supports access to all licensed dementia treatments and highlights the importance of regular review, carer involvement, and holistic care alongside medication.

Dosage and administration

Ebixa is available as 10 mg and 20 mg film-coated tablets and as a 10 mg/mL oral solution.

The recommended titration schedule is as follows: week 1, 5 mg once daily; week 2, 10 mg once daily; week 3, 15 mg once daily; week 4 and onwards, 20 mg once daily (the target maintenance dose).

Each increase should be made at a minimum interval of one week. If side effects occur during titration, the dose increase should be delayed until symptoms resolve.

Tablets are swallowed whole with water and may be taken with or without food.

The oral solution is measured using the dosing syringe provided in the pack and may be taken directly or mixed with water.

It should not be mixed with other liquids.

For patients with moderate renal impairment (creatinine clearance 30 to 49 mL/min), the recommended maintenance dose is 10 mg daily, with the possibility of increasing to 20 mg if well tolerated.

For severe renal impairment (creatinine clearance 5 to 29 mL/min), the dose should not exceed 10 mg daily.

No dosage adjustment is required for patients with mild to moderate hepatic impairment. Ebixa is not recommended for patients with severe hepatic impairment.

Expected benefits and treatment outcomes

It is essential to have realistic expectations about what Ebixa can achieve. Memantine does not reverse the damage caused by Alzheimer's disease or stop the disease from progressing.

The expected benefit is a slowing of cognitive and functional decline, which may be perceived by carers as a period of stability or a less rapid worsening of symptoms compared with what might otherwise have occurred.

Some patients and carers notice improvement in alertness, engagement, and the ability to perform daily activities during the first few months of treatment.

Others may not observe a noticeable change, though this does not necessarily mean the drug is ineffective; it may be slowing decline that would otherwise be more rapid.

Treatment response should be assessed by the prescribing clinician at 3 to 6 months and reviewed regularly thereafter.

Side effects of Ebixa

Common side effects

Common side effects include headache, dizziness, constipation, drowsiness (somnolence), and elevated blood pressure. These typically occur during the dose titration phase and often settle with continued treatment.

Ensuring adequate hydration and a diet with sufficient fibre can help manage constipation. Blood pressure should be monitored periodically.

Uncommon and rare side effects

Uncommon effects include confusion, hallucinations (visual or auditory), abnormal gait, fatigue, nausea, vomiting, urinary tract infection, and heart failure. Rare effects include seizures, psychotic reactions, pancreatitis, and hepatitis.

Very rare cases of Stevens-Johnson syndrome (a severe skin reaction) have been reported.

It can be difficult to distinguish side effects of memantine from the symptoms of advancing Alzheimer's disease.

New hallucinations, confusion, or behavioural changes should always be reported to the prescribing clinician, who can assess whether the symptoms are drug-related or disease-related and adjust treatment accordingly.

When to seek urgent medical advice

Carers should seek emergency medical help (call 999 or attend A&E) if the patient experiences seizures, sudden severe confusion, severe allergic reaction (swelling of face or throat, rash, breathing difficulty), chest pain, or unexplained falls.

Contact the GP or NHS 111 for persistent headache, worsening confusion, new behavioural symptoms, or signs of urinary infection.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Epilepsy and seizure risk

Memantine should be used with caution in patients with a history of epilepsy or seizures. NMDA receptor antagonists may lower the seizure threshold. If seizures occur during treatment, the prescriber should reassess the benefit-risk balance.

Cardiovascular conditions

Caution is advised in patients with recent myocardial infarction, uncompensated heart failure (NYHA class III to IV), or uncontrolled hypertension. Regular blood pressure monitoring is recommended.

Renal impairment and alkaline urine

Memantine is primarily excreted by the kidneys. Dose adjustment is required for moderate to severe renal impairment (see dosage section).

Conditions that alkalinise the urine (pH above 8), such as vegetarian diets, renal tubular acidosis, and severe urinary tract infections, may reduce renal clearance of memantine and increase plasma levels.

Clinical monitoring and possible dose reduction are advised.

Drug interactions

Memantine should not be used concurrently with other NMDA receptor antagonists (amantadine, ketamine, dextromethorphan), as the combined effect is unpredictable and may increase toxicity.

Drugs that use the same renal cation transport system (hydrochlorothiazide, cimetidine, ranitidine, procainamide, quinidine) may interact with memantine; monitoring is recommended.

Memantine may enhance the effects of dopaminergic agonists (levodopa, dopamine agonists) and anticholinergic drugs. Barbiturates and neuroleptics may interact with memantine.

How to get Ebixa in the UK

Ebixa (memantine) is a prescription-only medicine available on the NHS.

Treatment is typically initiated by a specialist in dementia care (old age psychiatrist, neurologist, or geriatrician) following a comprehensive assessment including cognitive testing, brain imaging, and exclusion of other causes of cognitive decline.

Once the dose is established and the patient is stable, ongoing prescribing may be managed by the GP under a shared care arrangement.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Many patients with dementia will qualify for exemption from prescription charges based on age (those aged 60 and over are exempt).

Generic memantine is available and is generally less expensive than the branded Ebixa product.

Supporting someone with Alzheimer's disease

Caring for a person with Alzheimer's disease is demanding and can be physically and emotionally exhausting.

Alongside medication, a range of support services is available through the NHS, local authorities, and charities. The Alzheimer's Society (alzheimers.org.uk) provides information, support groups, and a national helpline.

NHS memory services offer ongoing assessment, therapy (including cognitive stimulation therapy), and support for carers.

Social services can provide needs assessments for both the patient and carer, potentially including respite care, home adaptations, and personal care support.

Maintaining routines, using memory aids (such as whiteboards, clocks, and labelled cupboards), ensuring adequate nutrition and hydration, encouraging gentle physical activity, and providing social interaction are all important aspects of holistic dementia care that complement pharmacological treatment.

Sources

• Ebixa 10 mg Film-coated Tablets, Summary of Product Characteristics (EMC)
• Memantine hydrochloride, British National Formulary (BNF)
• NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
• Alzheimer's disease, NHS
• Alzheimer's Society
• MHRA Yellow Card Scheme